Predictors of gastroduodenal erosions in patients taking low‐dose aspirin
Open Access
- 2 December 2009
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 31 (1) , 143-149
- https://doi.org/10.1111/j.1365-2036.2009.04133.x
Abstract
Background Gastroduodenal ulcers are common in patients taking low‐dose aspirin. However, the factors predisposing to mucosal erosions, the precursor lesions, are not well known. Aims To examine the potential risk factors for the development of erosions in patients chronically taking low‐dose aspirin. Methods Patients included were taking aspirin 75–325 mg daily for >28 days. Exclusion criteria included use of nonsteroidal anti‐inflammatory and ulcer‐healing drugs. Demographic data were collected at baseline, prior to endoscopy to determine the frequency and number of erosions and Helicobacter pylori status. In those without ulcer or other exclusions, endoscopy was repeated at 3 months. Results Fewer patients had gastric erosions if they were H. pylori +ve (48.5% vs. 66.4% in H. pylori−ve patients at baseline, P = 0.17; 40.0% vs. 64.1% at 3 months, P = 0.029). If gastric erosions were present, they were also less numerous in H. pylori +ve patients (3.61 ± 0.83 vs. 4.90 ± 0.53 at baseline, P = 0.026; 2.17 ± 0.68 vs. 5.68 ± 0.86 at 3 months, P = 0.029). There was a trend (0.1 > P > 0.05) for more gastric erosions in those taking >100 mg/day aspirin. Males had more duodenal erosions at baseline (25.2% vs. 7.5%, P = 0.016). Patient age did not affect the presence or number of erosions. H. Pylori was not significantly associated with duodenal erosion numbers. Conclusions Helicobacter pylori infection may partially protect against low‐dose aspirin‐induced gastric erosions; damage to the stomach appears weakly dose‐related; and older age does not increase the risk of erosions.Keywords
This publication has 27 references indexed in Scilit:
- Canadian consensus guidelines on long‐term nonsteroidal anti‐inflammatory drug therapy and the need for gastroprotection: benefits versus risksAlimentary Pharmacology & Therapeutics, 2009
- Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirinAlimentary Pharmacology & Therapeutics, 2005
- Influence of sex and Helicobacter pylori on development and healing of gastroduodenal lesions in non-steroidal anti-inflammatory drug usersGut, 2002
- Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trialsAlimentary Pharmacology & Therapeutics, 2001
- Omeprazole Compared with Misoprostol for Ulcers Associated with Nonsteroidal Antiinflammatory DrugsNew England Journal of Medicine, 1998
- A Comparison of Omeprazole with Ranitidine for Ulcers Associated with Nonsteroidal Antiinflammatory DrugsNew England Journal of Medicine, 1998
- INDOMETHACIN DAMAGE TO RAT GASTRIC MUCOSA IS MARKEDLY DEPENDENT ON LUMINAL pHClinical and Experimental Pharmacology and Physiology, 1996
- Prophylactic aspirin and risk of peptic ulcer bleedingBMJ, 1995
- Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patientsBMJ, 1994
- Effect of Helicobacter pylori colonisation on gastric mucosal eicosanoid synthesis in patients taking non-steroidal anti-inflammatory drugs.Gut, 1993